166 related articles for article (PubMed ID: 18272471)
1. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer.
Kakehi Y; Kamoto T; Shiraishi T; Ogawa O; Suzukamo Y; Fukuhara S; Saito Y; Tobisu K; Kakizoe T; Shibata T; Fukuda H; Akakura K; Suzuki H; Shinohara N; Egawa S; Irie A; Sato T; Maeda O; Meguro N; Sumiyoshi Y; Suzuki T; Shimizu N; Arai Y; Terai A; Kato T; Habuchi T; Fujimoto H; Niwakawa M
Jpn J Clin Oncol; 2008 Feb; 38(2):122-8. PubMed ID: 18272471
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance for the management of prostate cancer in a contemporary cohort.
Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
[TBL] [Abstract][Full Text] [Related]
4. Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort.
Sugimoto M; Shiraishi T; Tsunemori H; Demura T; Saito Y; Kamoto T; Kakehi Y
Jpn J Clin Oncol; 2010 Oct; 40(10):973-9. PubMed ID: 20534686
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Ross AE; Loeb S; Landis P; Partin AW; Epstein JI; Kettermann A; Feng Z; Carter HB; Walsh PC
J Clin Oncol; 2010 Jun; 28(17):2810-6. PubMed ID: 20439642
[TBL] [Abstract][Full Text] [Related]
6. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen velocity in untreated, localized prostate cancer.
Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer.
Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F
Urol J; 2009; 6(1):27-30. PubMed ID: 19241338
[TBL] [Abstract][Full Text] [Related]
11. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
Abouassaly R; Lane BR; Jones JS
Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
13. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
14. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
15. Modeling prostate specific antigen kinetics in patients on active surveillance.
Zhang L; Loblaw A; Klotz L
J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
[TBL] [Abstract][Full Text] [Related]
16. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of anatomopathological results of radical prostatectomy specimen of patients who answer to criteria for active surveillance of prostate cancer].
Azancot V; Peyromaure M; Xylinas E; Descazeaud A; Cornud F; Vieillefond A; Saighi D; Amsellem-Ouazana D; Debré B; Zerbib M
Prog Urol; 2009 Oct; 19(9):619-23. PubMed ID: 19800552
[TBL] [Abstract][Full Text] [Related]
18. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer.
Choo R; Do V; Sugar L; Klotz L; Bahk E; Hong E; Danjoux C; Morton G; DeBoer G
Can J Urol; 2004 Feb; 11(1):2118-24. PubMed ID: 15003150
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.
Thomsen FB; Christensen IJ; Brasso K; Røder MA; Iversen P
BJU Int; 2014 May; 113(5b):E98-105. PubMed ID: 24053601
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
